A Phase I open-label, multi-center study of BGB-A317 evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of BGB-A317 in Chinese patients with advanced solid tumors.

Trial Profile

A Phase I open-label, multi-center study of BGB-A317 evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of BGB-A317 in Chinese patients with advanced solid tumors.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs BGB A317 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Aug 2017 According to a BeiGene media release, the company expected data from this study in 2017.
    • 30 Dec 2016 According to a BeiGene media release, first patient has been dosed in this trial. Professor Yilong Wu from Guangdong General Hospital is the lead principal investigator of the study.
    • 30 Dec 2016 Status changed from not yet recruiting to recruiting, as reported by a BeiGene media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top